New psoriasis drug candidate CAN10 passes first safety check in humans
NCT ID NCT06143371
First seen Feb 05, 2026 · Last updated May 06, 2026 · Updated 4 times
Summary
This early-stage study tested a new drug called CAN10 in 80 people to see if it is safe and how the body handles it. First, healthy volunteers received a single dose. Then, people with mild to moderate plaque psoriasis received multiple doses. The goal was to check for side effects and measure drug levels in the blood, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Berlin GmbH
Berlin, 13627, Germany
Conditions
Explore the condition pages connected to this study.